ApoB-100 Related Peptide Vaccine Protects Against Angiotensin II-Induced Aortic Aneurysm Formation and Rupture | Journal Scan

Study Questions:

Can a vaccine against apolipoprotein B (apoB)-100-related peptide prevent aortic aneurysm (AA) formation?

Methods:

Hyperlipidemic (apoE-/-) mice were immunized with p210 vaccine (directed against apoB-100-related peptide) and then treated with angiotensin II to induce AAs. Markers of inflammation were measured.

Results:

Mice treated with the p210 vaccine showed reduced AA formation and mortality due to AA rupture. This was associated with activation of CD8+ T cells, reduced expression of interleukin (IL)-6, MCP-1 and reduced macrophage infiltration in the aorta. The p210 vaccine decreased splenic Th17 cells, and CD8+ T cells from p210 immunized mice inhibited the polarization of CD4+ T cells into Th17 cells. IL-17A (-/-) mice were also protected from AA rupture.

Conclusions:

A p210 vaccine protected against Ang II-induced AA formation and mortality by reducing macrophage infiltration in the aorta and decreasing Th17 cell polarization. These findings provide a potentially novel immunomodulating approach against AA.

Perspective:

Abdominal aortic aneurysm (AAA) is relatively common in the elderly, especially in smokers. Rupture of AAA is associated with high mortality. Prevention of rupture is accomplished by close observation with surgical intervention when the aneurysm reaches a threshold diameter. Noninvasive interventions to prevent formation and/or expansion of AAA would be extremely useful. The current study provides a possible strategy for attenuating vascular inflammatory diseases. The specific role of apoB lipoproteins in aneurysm formation and the translational potential of this murine model of angiotension II-induced aneurysm formation to human aortic disease will require additional study.

Keywords: Angiotensin II Type 1 Receptor Blockers, Animals, Aorta, Aortic Aneurysm, Aortic Aneurysm, Abdominal, Aortic Rupture, Apolipoprotein B-100, Apolipoproteins E, CD4-Positive T-Lymphocytes, CD4-CD8 Ratio, Humans, Inflammation, Interleukin-17, Interleukin-6, Macrophages


< Back to Listings